Last reviewed · How we verify
Anti-VEGF Therapy
Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.
Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases. Used for Metastatic colorectal cancer (in combination with chemotherapy), Non-small cell lung cancer, Metastatic renal cell carcinoma.
At a glance
| Generic name | Anti-VEGF Therapy |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | VEGF inhibitor |
| Target | VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology, Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VEGF is a critical driver of angiogenesis (new blood vessel formation), which tumors and pathological tissues exploit to grow and spread. By inhibiting VEGF or its receptors, anti-VEGF agents starve these tissues of blood supply, reducing tumor growth and progression. This mechanism is used across multiple therapeutic areas including oncology, ophthalmology, and other conditions characterized by pathological neovascularization.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Non-small cell lung cancer
- Metastatic renal cell carcinoma
- Glioblastoma
- Wet age-related macular degeneration
- Diabetic retinopathy
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-VEGF Therapy CI brief — competitive landscape report
- Anti-VEGF Therapy updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI